M-A: Colchicine after percutaneous coronary intervention significantly reduces the risk of major adverse cardiovascular events in patients with symptomatic coronary artery disease.
9 Feb, 2022 | 08:25h | UTCRelated:
Expert Analysis | Colchicine in acute coronary syndrome: when to commence?
Review: Colchicine and the heart.
M-A: Colchicine administration for percutaneous coronary intervention
M-A: Efficacy and safety of low-dose colchicine in patients with coronary disease
Meta-analysis: Colchicine reduces new cardiovascular events in patients with coronary artery disease
Expert analysis: Efficacy and safety of colchicine in patients with chronic stable coronary disease
#ESCCongress – Randomized trial: Colchicine not beneficial for patients with acute coronary syndrome
Research: Colchicine Therapy and Plaque Stabilization in Patients With Acute Coronary Syndrome